Guardant Health (GH) Akcija Kursas
Guardant Health Kursas
Per pastaruosius 9 metus Guardant Health pajamos augo 52,3 % kasmet ir pasiekė 978,12 mln. USD. Guardant Health grynoji marža −42,6 % yra išaugo palyginti su −109,3 % prieš kelerius metus. Guardant Health 12 mėn. konsensuso tikslinė kaina yra 200,00 USD, apie virš kursą 37,4 %. Iš 36 analitikų 33 rekomenduoja pirkti — bendras konsensusas yra Pirkti.
Guardant Health akcijos kaina
Gaukite šiuos duomenis per Eulerpool API
100 000 užklausų/mėn. nemokamai · be kortelės
Guardant Health akcija ir akcijų analizė
Dažnai užduodami klausimai apie Guardant Health akciją
The main competitors of Guardant Health Inc in the market include companies such as Foundation Medicine, Exact Sciences Corporation, and Illumina Inc.
The business model of Guardant Health Inc. revolves around precision oncology and liquid biopsy. As a leading precision oncology company, Guardant Health develops and commercializes blood tests that can detect and monitor cancer. By analyzing the genetic alterations in circulating tumor DNA, Guardant Health enables oncologists to make more informed treatment decisions for their patients. The company's comprehensive liquid biopsy platform, including their flagship product Guardant360, provides a non-invasive alternative to traditional tissue biopsies. With their commitment to advancing cancer care, Guardant Health Inc. aims to improve patient outcomes through their innovative molecular diagnostics and therapeutic development solutions.
Guardant Health Inc is primarily active in the healthcare industry.
Guardant Health Inc. is a leading precision oncology company specializing in blood-based cancer tests. Founded in 2012, Guardant Health has rapidly grown to become a prominent player in the field of liquid biopsy. The company's breakthrough technology, Guardant360, enables comprehensive genomic profiling of solid tumors through a simple blood draw, facilitating personalized treatment decisions for cancer patients. With an extensive database of over 120,000 patients, Guardant Health Inc. is revolutionizing cancer diagnostics and therapy selection. Guardant Health is committed to advancing precision oncology and improving patient outcomes through its innovative genomic testing solutions.
Some significant milestones achieved by Guardant Health Inc include the successful completion of their initial public offering (IPO) in October 2018, generating over $235 million in funding. Additionally, the company's liquid biopsy test, Guardant360, received breakthrough device designation from the U.S. FDA in 2018, highlighting its potential impact in cancer diagnostics. Guardant Health Inc also expanded its global presence by establishing partnerships with several pharmaceutical companies and collaborating with research institutions. These achievements demonstrate Guardant Health Inc's growth as a leader in precision oncology, offering innovative solutions and advancing cancer care.
Guardant Health Inc is primarily present in the United States.
Guardant Health Inc represents values of innovation, precision, and compassion in the field of comprehensive cancer care. As a leading precision oncology company, Guardant Health is committed to transforming cancer treatment through advanced diagnostics and therapeutics. With their liquid biopsy technology, they aim to provide personalized and non-invasive genomic profiling, aiding in early cancer detection and treatment decisions. Guardant Health's corporate philosophy revolves around collaboration and empowerment, as they strive to improve patient outcomes and ease the burden of cancer. By combining cutting-edge technology with compassionate care, Guardant Health Inc epitomizes a commitment to revolutionizing cancer care for a better future.
Analitikai šiuo metu nustato vidutinę Guardant Health akcijos tikslinę kainą 203,40 USD (mediana: 200,00 USD), t. y. +40,1 % palyginti su paskutine kaina. Konsensusas pagrįstas 36 analitikų reitingais.
36 analitikai šiuo metu vertina Guardant Health akciją: 33 rekomenduoja pirkti, 3 laikyti ir 0 parduoti. 2026 m. analitikai tikisi, kad Guardant Health gaus 1,37 mlrd. USD pajamų ir −3,42 USD pelno akcijai.
Pagal dabartinį kursą Guardant Health akcija kainuoja 132,60 EUR (145,59 USD).
Guardant Health akcija (GH) kotiruojama 5 biržose, įskaitant: NASDAQ (GH), XETRA (5GH.DE), Frankfurt (5GH.F), München (5GH.MU), Düsseldorf (5GH.DU).
Guardant Health Inc. is a leading company in the field of liquid biopsy and cancer early detection. The company offers innovative solutions and technologies for cancer prevention, diagnosis, and therapy. Guardant Health has two different business units: Guardant360 and GuardantOMNI. Both divisions differ in their target audience and product portfolio. Guardant360 is a blood test that captures the DNA profile of tumor cells, thereby identifying the genetic fingerprint of cancer cells. This allows for more precise and faster diagnosis. The technology of Guardant360 is used by doctors and oncologists to analyze the genetic profiles of tumor cells in real-time and develop the best possible therapy for the patient. GuardantOMNI is a comprehensive cancer genomic test that covers over 500 genes, enabling an accurate diagnosis. GuardantOMNI is used by pharmaceutical companies to develop personalized therapies and drugs. Guardant Health is committed to advancing precision medicine in the field of cancer diagnostics and therapy. By using liquid biopsy technologies, doctors and oncologists can make accurate diagnoses and offer targeted therapy. Guardant Health has also partnered with renowned pharmaceutical companies such as Merck, Bristol-Myers Squibb, and Amgen to develop personalized therapies. In addition, the company has conducted its own clinical study on cancer early detection, and further studies are planned. The business model of Guardant Health is based on selling its products and solutions to medical facilities such as hospitals, laboratories, and oncologists. The company also generates revenue through partnerships with pharmaceutical companies and participation in clinical trials. Overall, Guardant Health is a company with a promising business model based on the use of liquid biopsy technologies. The company aims to revolutionize cancer diagnostics and therapy and offer personalized medicine. The wide portfolio of solutions and products from Guardant Health allows it to cater to the needs of doctors, oncologists, and pharmaceutical companies.
tikėtina pelnas Guardant Health yra 1,37 mlrd. USD. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.
tikėtina grynasis pelnas Guardant Health yra −439,68 mln. USD. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.
Kainų ir nuomos santykis (KGV) Guardant Health šiuo metu yra −42,60. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti Guardant Health akcijos vertę.
Kainų ir pardavimų santykis (KUV) Guardant Health šiuo metu yra 13,71. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra Guardant Health akcijos įvertinimo metrika.
Eulerpool kokybės balas Guardant Health yra 5/10.
Guardant Health ISIN yra US40131M1099. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.
Guardant Health WKN yra A2N5RY. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.
Guardant Health prekybos žymė yra GH. Ši biržos žymė naudojama Guardant Health akcijoms prekiauti biržoje.
Guardant Health akcija
Guardant Health Pagrindiniai konkurentai
Guardant Health Biržos simbolis
Guardant Health FIGI
Visos Guardant Health pagrindinės charakteristikos ir giluminė analizė
Mūsų akcijų analizė Guardant Health akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai Guardant Health. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: